RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by First Hospital of China Medical University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)First Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07373964, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histologically confirmed ES-SCLC, unsuitable for local radical therapy.

    Inclusion criterion 2

  3. Recovery from prior therapy toxicities to ≤ Grade 1 (except alopecia).

    Inclusion criterion 10

  4. ECOG performance status 0-1.

    Inclusion criterion 4

  5. At least one measurable lesion per RECIST v1.1.

    Inclusion criterion 5

  6. Other malignancy within past 5 years (except certain cured cancers).

    Exclusion criterion 4

    Immunodeficiency, HIV positivity, or organ transplant history.

    Exclusion criterion 6

  7. Effective contraception from consent until 180 days after last dose.

    Inclusion criterion 8

    Pregnancy, lactation, or unwillingness to use effective contraception.

    Exclusion criterion 8

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07373964, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥18 and ≤75 years.
  • Histologically confirmed ES-SCLC, unsuitable for local radical therapy.
  • No prior systemic therapy for ES-SCLC.
  • ECOG performance status 0-1.
  • At least one measurable lesion per RECIST v1.1.
  • Expected survival ≥3 months.
  • Adequate organ function (hematological, hepatic, renal, cardiac).
  • Effective contraception from consent until 180 days after last dose.
  • For active HBV infection: HBV DNA <2000 IU/mL within 28 days before treatment and on stable antiviral therapy.
  • Recovery from prior therapy toxicities to ≤ Grade 1 (except alopecia).
  • Signed informed consent.

Exclusion Criteria:

  • Factors significantly affecting oral drug absorption.
  • Prior HDAC inhibitor or immune checkpoint inhibitor therapy.
  • Known allergy to any study drug component.
  • Other malignancy within past 5 years (except certain cured cancers).
  • Participation in another clinical trial within 4 weeks.
  • Immunodeficiency, HIV positivity, or organ transplant history.
  • Uncontrolled cardiovascular disease or QTc >450 ms.
  • Pregnancy, lactation, or unwillingness to use effective contraception.
  • Other severe comorbid conditions deemed unsafe by investigator.
  • History of neurological or psychiatric disorders.
  • Any condition making the patient unsuitable per investigator judgment.

Quoted from ClinicalTrials.gov, NCT07373964, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07373964, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07373964